HV
Hikma Ventures
Corporate VCActiveHikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.
14
Investments
3
Exits
$250M
AUM
21.4%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Hikma Ventures.
Investment Thesis & Strategy
Hikma Ventures, as a CVC, invests in various stages of fintech, healthcare, and health diagnostics companies, leveraging its parent company's expertise in the pharmaceutical industry. They seek to strategically invest in companies that align with Hikma Pharmaceuticals' business objectives.
Investment Activity
Deals per year over the last 4 years
1
20192
20206
20213
2022Portfolio Companies
Selected investments from their portfolio of 14 companies
A
Alto Neuroscience
Biotech · Series B, 2022
V
Vytalize Health
Healthcare · Series B, 2022
S
Sollis Health
Healthcare · Series B, 2022
Q
Q-State Biosciences
Biotech · Series B, 2021
A
Astarte Medical
Healthcare · Series A, 2021
C
CareBridge
Healthcare · Series B, 2021
K
Koa Health
Healthcare · Series A, 2021
L
Lifebit
Biotech · Series B, 2021
C
Cellino
Biotech · Series A, 2021
A
Alto Pharmacy
Healthcare · Seed, 2020
E
EVERSANA
Healthcare · Growth, 2020
M
Medly Pharmacy
Healthcare · Series B, 2019
Notable Exits
CompanyTypeYearValue / Acquirer
EpharmixAcquisition2023—
AltoidaAcquisition2023—
MedopadAcquisition2020—
Frequently Asked Questions
Hikma Ventures focuses on Series A, Series B stage investments.